Literature DB >> 21503964

The role of TWIST as a regulator in giant cell tumor of bone.

Shalini Singh1, Isabella W Y Mak, Robert W Cowan, Robert Turcotte, Gurmit Singh, Michelle Ghert.   

Abstract

Giant cell tumor of bone (GCT) is an aggressive tumor consisting of multinucleated osteoclast-like giant cells and proliferating osteoblast-like stromal cells. Our group has reported that the stromal cells express high levels of the bone resorbing matrix metalloproteinase (MMP)-13, and that this expression is regulated by the osteoblast transcription factor Runx2. The purpose of this study was to determine the upstream regulation of Runx2 in GCT cells. Using GCT stromal cells obtained from patient specimens, we demonstrated that TWIST, a master osteogenic regulator, was highly expressed in all GCT specimens. TWIST overexpression downregulated Runx2 expression whereas TWIST siRNA knockdown resulted in Runx2 and MMP-13 upregulation. Interestingly, cells obtained from a GCT lung metastasis showed a reverse regulatory pattern between TWIST and Runx2. In mutational analysis, we revealed a point mutation (R154S) at the Helix2 domain of TWIST. This TWIST mutation may be an essential underlying factor in the development and pathophysiology of these tumors in that they lead to inappropriate TWIST downregulation of Runx2, arrested osteoblastic differentiation, and the maintenance of an immature and neoplastic phenotype.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21503964     DOI: 10.1002/jcb.23149

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

Review 1.  Twist: a molecular target in cancer therapeutics.

Authors:  Md Asaduzzaman Khan; Han-chun Chen; Dianzheng Zhang; Junjiang Fu
Journal:  Tumour Biol       Date:  2013-07-20

2.  Smad3 is the key to transforming growth factor-β1-induced osteoclast differentiation in giant cell tumor of bone.

Authors:  Zhiyuan Lou; Yi Yang; Tingting Ren; Shun Tang; Xianbo Peng; Qunshan Lu; Yifeng Sun; Wei Guo
Journal:  Med Oncol       Date:  2013-05-21       Impact factor: 3.064

Review 3.  Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer.

Authors:  Mousumi Tania; Md Asaduzzaman Khan; Junjiang Fu
Journal:  Tumour Biol       Date:  2014-06-02

4.  Investigation of FGFR2-IIIC signaling via FGF-2 ligand for advancing GCT stromal cell differentiation.

Authors:  Shalini Singh; Mohini Singh; Isabella W Y Mak; Robert Turcotte; Michelle Ghert
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

5.  MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone.

Authors:  Ting Wang; Huabin Yin; Jing Wang; Zhenxi Li; Haifeng Wei; Zhi'an Liu; Zhipeng Wu; Wangjun Yan; Tielong Liu; Dianwen Song; Xinghai Yang; Quan Huang; Wang Zhou; Jianru Xiao
Journal:  Oncotarget       Date:  2015-08-07

6.  Endothelial Twist1-PDGFB signaling mediates hypoxia-induced proliferation and migration of αSMA-positive cells.

Authors:  Akiko Mammoto; Tadanori Mammoto; Kathryn Hendee; Megan Muyleart
Journal:  Sci Rep       Date:  2020-05-05       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.